REG - Spectral MD Holdings - Appointment of Chief Operating Officer

Spectral MD HoldingsAnnouncement

09/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221109:nRSI7404Fa&default-theme=true

RNS Number : 7404F  Spectral MD Holdings, Ltd.  09 November 2022

 

Appointment of Chief Operating Officer

 

Accomplished technology executive and innovator Dr. Niko Pagoulatos joins
Spectral MD

 

LONDON, U.K AND DALLAS, TX, U.S. - Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI algorithms and optical
technology for rapid and accurate treatment decisions in wound care, announces
the appointment of Dr. Niko Pagoulatos as Chief Operating Officer, effective
this week.

 

As Chief Operating Officer of Spectral MD, reporting to CEO Wensheng Fan, Dr.
Pagoulatos will accelerate growth and operational performance of the Company
with specific focus on scientific research, engineering, product development
leading to global portfolio launch and clinical adoption.

 

Dr. Pagoulatos comes to Spectral MD as an accomplished technology executive
and innovator with 25+ years of experience in engineering, clinical and
business aspects of specialized medical ultrasound imaging. Dr. Pagoulatos is
a team-oriented and results-driven leader with extensive experience and a
strong track record in building and leading cross-functional teams to
successfully commercialize innovative medical technologies with global
clinical impact.

 

Dr. Pagoulatos has held multiple executive roles including Chief Innovation
Officer, Chief Operating Officer, and most recently, Chief Technology Officer
at EchoNous, a global healthcare innovation company headquartered in Seattle
focused on the development and commercialization of the first AI-assisted
handheld ultrasound tool to increase diagnostic confidence at the bedside.

 

Dr. Pagoulatos earned his B.S. in Physics from the University of Athens in
Greece and completed his graduate studies at the University of Washington in
Seattle, where he earned a M.S. in Bioengineering in addition to a M.S. and
Ph.D. in Electrical Engineering.

 

Niko Pagoulatos, Chief Operating Officer of Spectral MD, said: "I am impressed
with Spectral MD's wound healing assessment breakthrough technology, and I am
excited to join its world-class team. I look forward to applying my experience
and expertise to help Spectral MD build on its success, release its
breakthrough DeepView™ technology into the market, and execute on its
strategic goals to revolutionize wound care management worldwide."

 

Wensheng Fan, Chief Executive Officer of Spectral MD, said: "Niko is a
transformational leader and proven industry innovator with deep experience in
medical ultrasound imaging, product innovation, and groundbreaking AI
solutions. As an innovative and seasoned executive, I am confident his broad
operational experience will be critically important as we continue to manage
our growth, scaleup operations and seek to bring DeepView™ through
development and into the market. I am truly delighted to welcome Niko to the
Spectral MD team."

 

Proactive Investors interview with COO, Niko Pagoulatos

 

 

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
                                                   (mailto:spectralMD@walbrookpr.com)
 Paul McManus / Alice Woodings                     Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

Further background on Dr. Pagoulatos

Dr. Pagoulatos comes to Spectral MD as an accomplished technology executive
and innovator with 25+ years of experience in engineering, clinical and
business aspects of specialized medical ultrasound imaging. Dr. Pagoulatos is
a team-oriented and results-driven leader with extensive experience and a
strong track record in building and leading cross-functional teams to
successfully commercialize innovative medical technologies with global
clinical impact. Dr. Pagoulatos invented several breakthrough ultrasound
technologies that include key industry-first features and holds authorship on
ten patents and multiple scientific publications. Additionally, Dr. Pagoulatos
is one of the first researchers in the world to develop algorithms for the
real-time fusion of ultrasound and magnetic resonance imaging.

 

Dr. Pagoulatos has held multiple executive roles including Chief Innovation
Officer, Chief Operating Officer, and most recently, Chief Technology Officer
at EchoNous, a global healthcare innovation company headquartered in Seattle
focused on the development and commercialization of Kosmos, the first
AI-assisted handheld ultrasound tool to increase diagnostic confidence at the
bedside. In these roles, he shaped the Company's vision and mission,
synthesized global market and clinical data, drove technology development and
product roadmaps, as well as managed multimillion-dollar cross-functional team
budgets. While at EchoNous, Dr. Pagoulatos built and led a team that developed
and released to global markets the innovative handheld ultrasound tool Kosmos,
the only AI-driven handheld ultrasound tool benchmarked against cart-based
ultrasound systems with several industry-first technologies and features. Dr.
Pagoulatos and his team delivered 510(k) clearance and CE mark for Kosmos in
four years from company inception and obtained several certifications,
including ISO 13485.

 

Prior to EchoNous, Dr. Pagoulatos held Director and advanced development
engineering roles at FUJIFILM SonoSite, the world leader in point-of-care
ultrasound (POCUS). During his tenure, Dr. Pagoulatos led the productization
and global market release of several innovative products including advanced
needle visualization, a well-established ultrasound imaging feature for
ultrasound-guided needle procedures in POCUS, and a portable ultrasound device
iViz, FUJIFILM Sonosite's first tablet-form-factor ultrasound system designed
for high-mobility. Additionally, Dr. Pagoulatos has held Senior Scientist
roles within the Ultrasound Division of Siemens Healthineers and DYSIS
Medical. At Siemens, Dr. Pagoulatos led the development and integration of a
real-time 3D processing and visualization module into the first 4D ultrasound
scanner released by the company. At DYSIS Medical, he developed a spectral
imaging registration algorithm and led the software development effort of an
innovative dynamic spectral imaging device designed for non-invasive detection
of cervical cancer.

 

Dr. Pagoulatos earned his B.S. in Physics from the University of Athens in
Greece and completed his graduate studies at the University of Washington in
Seattle, where he earned a M.S. in Bioengineering in addition to a M.S. and
Ph.D. in Electrical Engineering.

 

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(™)
Imaging System.

www.spectralmd.com

info@spectralmd.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPGMPGUPPGMR